All In Biotech

Drug Trial Radar · NCT05498428

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

520

Planned (sponsor's estimate)

Start

Nov 11, 2022

Primary completion

Aug 17, 2027

Study completion Aug 18, 2028

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Aug 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).

Conditions

  • Carcinoma, Non-small-Cell Lung

Interventions

  • AmivantamabDrug

    Amivantamab will be administered subcutaneously by manual injection.

  • LazertinibDrug

    Lazertinib will be administered as an oral tablet.

  • CarboplatinDrug

    Carboplatin will be administrated by IV infusion.

  • PemetrexedDrug

    Pemetrexed will be administered by IV infusion.

  • Direct Oral Anticoagulant (DOAC)Drug

    DOAC will be administered orally.

  • Low Molecular Weight Heparin (LMWH)Drug

    LMWH will be administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All Cohorts Except Cohort 4: Objective Response Rate (ORR) Based on Investigator Assessment (INV)Time frame: Up to 1 year 6 months
  2. Cohort 4: Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 4 years and 9 months
  3. Cohort 4: Number of Participants with AEs by SeverityTime frame: Up to approximately 4 years and 9 months
  4. Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory ValuesTime frame: Up to approximately 4 years and 9 months
  5. Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values by SeverityTime frame: Up to approximately 4 years and 9 months

Locations

110 sites in 12 countries. Site status is shown where the registry gives one.

  • University of California at San Diego

    La Jolla, California · Recruiting

  • University of California Irvine

    Orange, California · Recruiting

  • Stanford Cancer Institute

    Stanford, California · Recruiting

  • Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital

    Washington D.C., District of Columbia · Recruiting

  • Baptist Lynn Cancer Institute

    Boca Raton, Florida · Completed

  • Mount Sinai Medical Center

    Miami Beach, Florida · Recruiting

  • AdventHealth

    Orlando, Florida · Recruiting

  • H. Lee Moffitt Cancer & Research Institute

    Tampa, Florida · Completed

  • University of Kansas Cancer Center

    Westwood, Kansas · Recruiting

  • Sidney Kimmel Cancer Center - Bayview Campus

    Baltimore, Maryland · Recruiting

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • Washington University School Of Medicine

    St Louis, Missouri · Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • Hematology-Oncology Associates of CNY

    East Syracuse, New York · Completed

  • Novant Health 1

    Charlotte, North Carolina · Completed

  • Novant Health

    Winston-Salem, North Carolina · Completed

  • Cleveland Clinic 1

    Cleveland, Ohio · Completed

  • Cleveland Clinic

    Cleveland, Ohio · Completed

  • Cleveland Clinic 2

    Mayfield Heights, Ohio · Completed

  • Cleveland Clinic 3

    Warrensville Heights, Ohio · Completed

  • The Huntsman Cancer Institute

    Salt Lake City, Utah · Completed

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Providence Regional Cancer Partnership

    Everett, Washington · Completed

  • Virginia Mason Medical Center

    Seattle, Washington · Completed

  • Swedish Cancer Institute

    Seattle, Washington · Recruiting

  • Fundacao Pio XII

    Barretos, Brazil · Recruiting

  • PERSONAL Oncologia de Precisao e Personalizada

    Belo Horizonte, Brazil · Recruiting

  • Hospital do Cancer de Londrina

    Londrina, Brazil · Recruiting

  • Hospital Moinhos de Vento

    Porto Alegre, Brazil · Recruiting

  • IDOR - Regional Rio de Janeiro

    Rio de Janeiro, Brazil · Recruiting

  • IDOR - Regional Bahia

    Salvador, Brazil · Recruiting

  • Hospital Alemao Oswaldo Cruz

    São Paulo, Brazil · Recruiting

  • Impar Servicos Hospitalares SA Hospital Nove de Julho

    São Paulo, Brazil · Completed

  • Fundacao Antonio Prudente A C Camargo Cancer Center

    São Paulo, Brazil · Recruiting

  • Affiliated Hospital of Hebei University

    Baoding, China · Completed

  • Jilin cancer hospital

    Changchun, China · Recruiting

  • Sichuan Cancer Hospital

    Chengdu, China · Recruiting

  • West China Hospital Sichuan University

    Chengdu, China · Recruiting

  • The First Affiliated Hospital of PLA Army Medical University

    Chongqing, China · Recruiting

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.